ABSTRACT Objective: To evaluate the level and the persistence of maternal antibodies in infants after maternal immunization with pneumococcal polysaccharide vaccine (Pn23V). Methods: Pregnant women were assigned to two groups, during routine low-risk pre-natal visits. The first Group (VAC) received the Pn23V vaccine shortly after enrolment at 28 weeks or later, and the second Group (NO_VAC) received no vaccine. To investigate the antibody persistence, we collected blood samples from the mothers after 1 month of delivery and from the infants at 1 and 6 months of age. Results: Antibody titers were measured for serotypes 1, 6B and 14. Geometric mean antibody concentrations of specific immunoglobulin G were significantly higher in the vaccinated group compared with unvaccinated controls for all three serotypes tested. Conclusion: Despite the antibody level's decline, at 6 months of age, proportions >0.35 lg/ml remained higher in the infants of vaccinated mothers than controls for all three serotypes. A 10-valent PCVs (PCV-10) were included in the Brazilian vaccination schedule in the end of 2010. The current immunization schedule offers the first dose of vaccine at 2-3 months, and the second dose at 4-5 months of age. Although the coverage of vaccination programs is increasing, many children still receive their vaccines late and do not necessarily get all scheduled doses [4] .
I N T R O D U C T I O N
Pneumococcal polysaccharide conjugate vaccines (PCVs) have been found to be immunogenic in the first year of life in several studies, reducing the incidence of invasive pneumococcal diseases and decreasing nasopharyngeal carriage of pneumococcal serotypes included in the vaccines [1] [2] [3] .
A 10-valent PCVs (PCV-10) were included in the Brazilian vaccination schedule in the end of 2010. The current immunization schedule offers the first dose of vaccine at 2-3 months, and the second dose at 4-5 months of age. Although the coverage of vaccination programs is increasing, many children still receive their vaccines late and do not necessarily get all scheduled doses [4] .
Immunization of pregnant women with polyvalent pneumococcal polysaccharide vaccine might boost maternal immunity against Streptococcus pneumoniae and, as a result, can provide protection for their infants against pneumococcal disease during the first few months of life. Enhanced transplacental antibody transfer and increased provision of secretory antibody in mother's milk are responsible for this protection [5, 6] .
Antibody levels >0.35 mg/ml have been correlated with short-term protection in pediatric studies.
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Several studies, most of them conducted in Asia and Africa, evaluating the protection and serotype antibody levels in infants from mothers vaccinated with 23-valent pneumococcal polysaccharide vaccine (Pn23V) during pregnancy have already been published [8] [9] [10] [11] [12] [13] [14] . However, there is no published study evaluating healthy pregnant women vaccinated with Pn23V in Latin America. The single study in Brazil evaluating Pn23V in pregnant women and persistence of maternal antibodies included only infants born to human immunodeficiency virus-infected mothers [14] .
Data from the Brazilian surveillance system for meningitis showed a decreased number of cases of pneumococcal meningitis in children <2 years after inclusion of PCV-10 in 2010. However, this decrease could not be observed when infants <6 months were considered. The incidence rate of pneumococcus meningitis in infants between 6 and 11 months decreased from 7.93 per 100,000, before inclusion of the PPV, to 2.58 per 100,000 in 2011. However, the incidence rate of pneumococcal meningitis in infants <6 months was 8.02 per 100,000 before inclusion of PCV, in 2011; after inclusion of the PPV, the incidence rate of pneumococcal meningitis in this same age bracket was 8.17 per 100,000 [15] .
To circumvent the obstacles in protecting the young infants, a solution could be to immunize mothers so that an increased concentration of protective maternal antibodies could be transferred through the placenta to the fetus.
Our objective was to evaluate the level and the persistence of maternal antibodies in infants after maternal immunization with pneumococcal polysaccharide vaccine in a period before the introduction of PCV in the Brazilian vaccination schedule.
M E T H O D S
This study was carried out in the outpatient clinic of the Hospital São Luiz Gonzaga in the city of São Paulo during the period May 2006-January 2007, which was before the introduction of PCV in the Brazilian vaccination schedule. After providing written informed consent, pregnant women were randomly assigned to one of three groups for the study. Group 1 receive no vaccine, Group 2 received PS-23 at 30-34 weeks of gestation and Group 3 received PS-23 after delivery. For the present study, the Group 3 was excluded.
The inclusion criteria were age 15-40 years, with an uncomplicated pregnancy and 30-34 gestation weeks; women should not have been at risk for complicated labor, and be without antecedents of a previous complicated pregnancy. All participants provided a written informed consent, and the study was approved by the Research Ethics Committee of the Hospital Santa Casa de Misericordia de São Paulo.
After providing written informed consent, pregnant women were randomly assigned to one of the three groups based on a randomized list during routine low-risk pre-natal visits. The first group (VAC) received the Pn23V vaccine shortly after enrolment (pregnant women at 28 weeks), and the second group (NO_VAC) received no vaccine (Fig. 1) . For the present study, the Group 3 was excluded. A total of 100 pregnant women included in Group VAC and Group NO_VAC were included in the study.
Adverse reactions like local reactions at injection site (redness, swelling, induration and/or pain), as well as systemic reactions including fever, were followed up by phone for 24 h after vaccination. A month later, participants were questioned about other adverse events during routine evaluation.
To investigate the antibody persistence, we collected blood samples from the mothers after 1 month of delivery and from the infants at 1 and 6 months of age. Antibody geometric mean concentrations (GMCs) were measured for serotypes 1, 6B and 14. These three serotypes were the most frequent serotypes causing invasive pneumococcal infections in children <5 years old in Brazil in the period of the study [16] .
The sera were sent to the World Health Organization reference laboratory for pneumococcal serology at the Institute of Child Health (London) for the antibodies measurement. Serum was assayed for antibodies to three individual pneumococcal capsular polysaccharides using an enzyme-linked immunosorbent assay after adsorption with both cellwall polysaccharide and 22F polysaccharide, as described elsewhere [17] .
The database was stored on EpiInfo for Windows (v. 3.4.3) . In this article, we estimated the geometric means, with their respective 95% confidence interval (95% CI), of antibody GMCs for serotypes 1, 6B and 14 among infants at 1 and 6 months of age. We compared these GMC from infants born to vaccinated mothers with those born to non-vaccinated mothers. infants with GMC > 0.35 mg/ml and >1 mg/ml were also compared.
R E S U L T S
All the 100 women recruited for this study gave birth to at-term healthy babies (50 women were assigned to each group), of whom 92 completed the followup at 3 months of age (45 in Group VAC and 47 in Group NO_VAC), and 88 infants completed the follow-up at 6 months of age (42 in Group VAC and 46 in Group NO_VAC). No vaccine adverse reaction was informed by the pregnant women. None of the infants received conjugated pneumococcal vaccine during the first year of life, as the inclusion of the conjugate vaccine in the Brazilian schedule begun after the end of the trial.
Mother's immunization induced antibody responses to all serotypes tested ( Table 1) . GMCs of specific immunoglobulin G (IgG) were significantly higher in the vaccinated group compared with unvaccinated controls for all three serotypes tested.
A significantly higher proportion of vaccinated mothers achieved protective concentrations of IgG to serotype 1 compared with unvaccinated controls. However, proportions above both 0.35 and 1. mg/ml were relatively high for serotypes 6B and 14 in unvaccinated mothers.
For the infants at 1 month of age, GMCs and proportions >0.35 and 1.0 mg/ml were significantly higher in the infants born from mothers who received vaccine compared with infants born from unvaccinated mothers. At 1 month of age, infant IgG to serotypes 1, 6B and 14 were 19.6, 20.8 and 20.8% of the maternal levels. By 6 months of age, antibody levels had dropped by >90% for all three serotypes. Despite this rapid decline in antibody, at 6 months of age, proportions >0.35 mg/ml remained higher in the infants of vaccinated mothers than controls for all three serotypes, although the difference in proportions >1.0 mg/ml had been significant only for serotype 14. Table 1 shows the distribution of GMCs in groups and the percentage of children with proportions of serotypes >0.35 mg/ml and 1 mg/ml.
D I S C U S S I O N
Maternal immunization has been suggested as a way to protect neonates and young infants against pneumococcal invasive infection [5, 6] . Maternal immunization may protect infants because of the increased antibody concentrations of transferred antibodies across the placenta as well as from increased antibody concentrations in breast milk (8, 18] . We report here that vaccinating mothers during pregnancy gives to the newborn infants significantly higher serum anti-polysaccharide antibody concentrations at 1 month. Because the number of subjects included in this report was too small for evaluating clinical outcomes, we were not able to demonstrate that maternal pneumococcal polysaccharide vaccine provides protection against pneumococcal infections in a previous report. However, exclusive maternal breastfeeding until the age of 6 months protected infants against respiratory infections [19] .
Previous studies have shown that administration of non-conjugated bacterial polysaccharide vaccines to children or adults impairs anti-capsular antibody response to subsequent injections of polysaccharide or conjugate vaccines [20] . There are no data about this effect in infants after the use of vaccine in pregnancy.
In this study, maternal immunogenicity of the 23V vaccine was good, as >90% of the mothers achieved good antibody levels after immunization. The antibody levels for the three serotypes measured (1, 6B and 14) were higher in infants of vaccinated mothers. However, for serotypes 1 and 6B the difference between vaccinated and unvaccinated was more evident. Serotype 14 antibody titers were high even in the non-vaccinated group of pregnant Brazilian women (85% of them with >1.0 mg/ml), probably because this serotype is the most frequent in infections in the general population [19] . This finding was described by others authors. Quiambau et al. [13] found that >60% of pregnant women had high antibody levels for six serotypes.
Other authors have shown differences in the serotypes with increased maternal antibodies after vaccination with Pn23V. Lehmann et al. [11] observed increase in serotype 5, 14 and 19F. Munoz et al. [12] showed significant increase in antibody titers of serotypes 6B and 19F.
In our study, antibody titer after 1 month of age was potentially protective for the disease (>0.35 mg/ml) in 93.2% for serotype 1, 84.1% for serotype 6B and 95.5% for serotype 14 in the vaccinated group. However, at 6 months of age the antibody titer decreased, but maintained protective level in 71.1% of infants for serotype 14.
The antibody titer at 1 month of age of the vaccinated group was potentially protective for colonization (>1 mg/ml) in 65.9% for serotype 1 and 6B and 93.2% for serotype14. Lehmann et al. [11] observed persistence of high titers of serotypes 5 and 23F up to 2 months. Munoz et al. [12] observed persistence of antibodies up to 7 months of age. Holmlund et al. [18] showed a decrease in antibody levels at 4 months. It is important to emphasize that this study is the first in Latin America evaluating normal pregnancies.
We can conclude that mothers vaccinated with polysaccharide vaccine 23V respond with an increase in antibody titer, and that these antibodies are transmitted to their infants with protective titers remaining until at least 1 month of age. Immunization during pregnancy has the potential to protect the infant before the beginning of immunization schedule of PCV.
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